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Background: Cytologic examination of a fine-needle aspiration biopsy specimen cannot distinguish between
benign and malignant follicular or Hürthle cell neoplasms. Serum thyroglobulin (Tg) concentrations are higher in
follicular and Hürthle cell carcinomas than in benign follicular or Hürthle cell tumors, but preoperative measurement
of Tg is not recommended for initial evaluation of thyroid nodules. The aim of this study was to find out whether
preoperative serum Tg concentration is a predictive factor of malignant disease in patients with a follicular or
Hürthle cell neoplasm with a diameter of 2 cm or less.
Methods: From 1988 to 2013, a total of 244 patients (214 female, 30 male, age range 9 to 82 years, median
age 52 years) had a surgical procedure at our institute because of follicular or Hürthle cell neoplasms with a
tumor diameter of 2 cm or less. In these patients a preoperative concentration of Tg was determined and
Tg-autoantibodies were negative. The risk factors for malignancy were identified by a chi-square test and
multivariate logistic regression.
Results: The histopathologic diagnoses were carcinoma, adenoma, and benign goiter in 62 (25.5%), 115 (47%),
and 67 (27.5%) patients, respectively. The median preoperative Tg concentration in benign tumors, papillary
carcinomas, follicular carcinomas, and Hürthle cell carcinomas was 41, 87, 72, and 106 ng/ml (P = 0.05), respectively.
The predictive factors for carcinoma shown by the chi-square test were: sex, thyroid volume, and preoperative Tg
concentration. The independent predictors of malignancy as shown by multivariate logistic regression were: male
sex (odds ratio, 2.57; P = 0.02), and a Tg concentration of more than 80 ng/ml (odds ratio, 2.35; P = 0.005).
Conclusion: The independent predictors of malignancy in follicular or Hürthle cell neoplasms are sex and
preoperative Tg concentration.
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Thyroid nodules are a common clinical problem [1], and
harbor thyroid cancer in 5% to 15% of cases [2]. A thyroid
nodule is most accurately evaluated by an ultrasound-
guided fine-needle aspiration biopsy (FNAB) [1]. However,
in the preoperative diagnosis of follicular and Hürthle cell
tumors, FNAB has limited usefulness [3-5]. In follicular
and Hürthle cell tumors, malignancy is confirmed by* Correspondence: nbesic@onko-i.si
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unless otherwise stated.demonstration of transcapsular or vascular invasion,
which cannot be seen on cytologic slides [3,6-9]. In follicu-
lar or Hürthle cell neoplasms, cytology cannot distinguish
a malignant tumor from a benign one [8,9]. Confirmation
of malignancy is possible only with histological examination
of the tumor. Therefore, patients with an FNAB-proven
follicular or Hürthle cell neoplasm should be treated sur-
gically. Unfortunately, intraoperative frozen-section ana-
lysis is not reliable and does not affect intraoperative
decision-making [10,11].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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American Thyroid Association guidelines recommend a
lobectomy or total thyroidectomy [1]. Total thyroidec-
tomy is preferable in patients who have bilateral nodular
disease, who have large tumors (>4 cm), when marked
atypia is seen on the biopsy, or who prefer to undergo
bilateral thyroidectomy to avoid the possibility of requir-
ing future surgery on the contralateral lobe [1]. A comple-
tion of thyroidectomy may be necessary if malignancy is
confirmed by histologic examination after a lobectomy
[1]. Reliable predictive factors for malignancy are needed,
to decrease the number of thyroid reoperations [12-14].
The levels of thyroglobulin (Tg) can be elevated in many
thyroid diseases [1,15]. So, according to the European and
American Thyroid Associations, preoperative Tg measure-
ment is an insensitive and non-specific diagnostic test for
thyroid cancer [1,15]. In subjects with mild-to-moderate
iodine deficiency, the serum Tg concentration correlates
with the size of the goiter, the presence of multinodularity
and intake of iodine [16]. Furthermore, the thyroid vol-
ume, as well as the Tg concentration, is inversely related
to iodine intake [16]. However, our previous studies in
patients with large follicular or Hürthle cell neoplasms
(median size 3 cm) showed that measurement of the pre-
operative serum Tg concentration may represent a useful
preoperative diagnostic test. Namely, the concentration of
serum Tg was higher in follicular and Hürthle cell cancers
than in benign neoplasms [12-14]. However, the majority
of thyroid neoplasms are smaller than 2 cm [17]. The aim
of our retrospective study was to find out if serum Tg is a
predictive factor for malignancy in follicular or Hürthle
cell neoplasms with a diameter of 2 cm or less.
Methods
Patients
A chart review of 244 patients (214 female, 30 male, age
range 9 to 82 years, median age 52 years) was perfor-
med. These patients had a surgical procedure at our in-
stitute from 1988 to 2013 because of follicular or Hürthle
cell neoplasms with a diameter of 2 cm or less. In all
patients, the preoperative concentration of Tg was de-
termined and a test for Tg-autoantibodies was negative.
The clinical data of these patients are presented in
Table 1. All patients (N = 38) with Tg-autoantibodies were
excluded from our analysis.
All patients had a follicular or Hürthle cell neoplasm
diagnosed by FNAB and cytology. FNABs were ultra-
sound-guided in the majority of cases. FNABs were per-
formed using a 21-23 gage needle attached to a 10 ml
syringe. All cytologic slides were examined by cytopa-
thologists and histologic slides by pathologists, all of
them experienced in thyroid pathomorphology. Routine
cytologic and final pathology reports were used in this
study.Clinically, the dominant nodule was either solitary or
in a multinodular goiter in 160 and 84 cases, respectively
(Table 1). The sizes of the thyroid gland and the dominant
nodule were determined on the basis of measurements
performed during the pathologic examination of the
biopsy material. The thyroid volume was calculated
by summing the volumes of both lobules. The volume
of each lobe was calculated using the formula:
Maximal lengthWidth Depth π=6
as already reported [14].
Our study was reviewed and approved by the Institu-
tional Review Board of the Institute of Oncology, Ljubljana.
It was performed in accordance with the ethical stan-
dards laid down in an appropriate version of the 1964
Declaration of Helsinki. Our study was conducted with
the understanding and consent of the subjects. All our
patients were asked during first admission to our insti-
tute or a follow-up visit to give consent for the study of
their charts and biopsy material for scientific purposes.
Since the Institutional Review Board of the Institute of
Oncology Ljubljana approved this specific study, our pa-
tients were not asked to give written consent on this
specific study.
Laboratory
From 1988 to 2001 and from 2007 to 2008, serum Tg
measurements were carried out using the commercially
available Dyno-test Tg/Tg-S RIA kit (Henning/Brahms,
Germany), which includes the determination of Recovery-
Tg. Normal values of Recovery-Tg were considered to rule
out the possibility of disturbing influence exerted by
Tg-autoantibodies or other non-specific serum proteins.
From 2001 to 2007, serum Tg and Tg-autoantibody con-
centrations were determined by the commercially avail-
able LIAISON Tg and LIAISON Anti-Tg kits, respectively,
with the LIAISON analyzer (all from Byk-Sangtec Diag-
nostica/DiaSorin, Germany/Italy). From 2008 onwards,
serum Tg and Tg-autoantibody concentrations were de-
termined by the commercially available Tg/Tg-II Cobas
and Anti-Tg kits, respectively, with a Modular analyzer
(all from Roche, Germany).
Owing to the presence of Tg-autoantibodies, 38 pa-
tients were excluded from the study.
Statistical analysis
The predictive factors for malignancy were identified by
a chi-square test. Only the status of the dominant nod-
ule was used for the analysis of factors correlating with
the presence of malignancy. A receiver operating charac-
teristic (ROC) analysis was performed to define the cut-
off for Tg levels. A cut-off for Tg values was chosen at
80 ng/ml on the basis of a ROC curve. The sensitivity,
Table 1 Clinical data of 244 patients with follicular and Hürthle cell neoplasms with diameter 2 cm or less
Characteristic Subgroup Benign N = 182 (%) Carcinoma N = 62 (%) Chi-square test P value
Age (years) 45 or younger 57 (24%) 23 (9%) 0.44
Older than 45 125 (51%) 39 (16%)
65 or younger 163 (67%) 54 (22%) 0.64
Older than 65 19 (8%) 8 (3%)
Sex Male 17 (7%) 13 (5%) 0.024
Female 165 (68%) 49 (20%)
Dominant tumor In multinodular goiter 61 (25%) 23 (9%) 0.64
Solitary 121 (50%) 39 (16%)
Tumor diameter (cm) 1 or less 42 (17%) 13 (5%) 0.86
More than 1 140 (58%) 49 (20%)
Thyroid volume (ml) 29 or less 149 (61%) 47 (19%) 0.36
30 or more 33 (14%) 15 (6%)
49 or less 169 (70%) 52 (21%) 0.045
50 or more 13 (5%) 10 (4%)
Serum Tg concentration (ng/ml) 79 or less 120 (49%) 28 (11%) 0.004
80 or more 62 (26%) 34 (14%)
299 or less 168 (69%) 51 (21%) 0.031
300 or more 14 (6%) 11 (4%)
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elevated Tg concentrations for the presence of carcin-
oma were calculated. The following factors were inclu-
ded in the univariate and multivariate statistical analyses:
the sex of the patients, volume of the thyroid gland, and
Tg concentration. The variables that showed statistical
correlation (P < 0.05) by logistic regression analysis were
considered as independent predictive factors for malig-
nancy. SPSS 16.0 for Windows was used for statistical
analysis.
Results
The median age of the patients, tumor size, volume of
the thyroid gland, median and mean concentration of
preoperative Tg were 52 years (range, 9 to 82), 1.5 cm
(range, 0.4 to 2), 20 ml (range, 5 to 162), 50 ng/ml
(range, 1 to 3,424), and 125 (range 1 to 3,424) ng/ml, re-
spectively. The histopathologic diagnoses were carcinoma,
adenoma, and benign goiter in 62 (25.5%), 115 (47%), and
67 (27.5%) patients, respectively.
The median age of patients with carcinoma was
52.5 years, while the median age of those with a benign
disease was 52 years. The median size of the tumor was
1.55 cm in patients with carcinoma and 1.5 cm in those
with a benign disease. Tumor diameter did not correlate
with malignancy rate (P = 0.225). These data are presented
in Table 2 and Figures 1 and 2.
The median preoperative Tg concentrations in patients
with and without carcinoma were 86 and 41 ng/ml,
respectively. The mean preoperative Tg concentrationsin patients with and without carcinoma were 215 and
95 ng/ml, respectively. The median preoperative Tg
concentrations in benign tumors, papillary carcinomas,
follicular carcinomas, and Hürthle cell carcinomas were
41, 87, 72, and 106 ng/ml (P < 0.05), respectively. The
mean preoperative Tg concentrations in benign tumors,
papillary carcinomas, follicular carcinomas, and Hürthle cell
carcinomas were 95, 147, 433, and 269 ng/ml (P < 0.001),
respectively. Tg concentrations in different types of carcin-
oma in the dominant nodule are listed in Table 3. As
shown by logistic regression analysis, concentration of Tg
(cut-off point of 80 ng/ml) was an independent predictive
factor. The ROC analysis showed that the area under the
curve was 0.613 (P = 0.008). The sensitivity and specificity
of the test, positive predictive value, and negative predict-
ive value (cut-off = Tg concentration of 80 ng/ml) for the
presence of carcinomas in small follicular and Hürthle cell
neoplasms of the thyroid gland were 54.8%, 31.1%, 35.4%,
and 81%, respectively.
Predictive factors for malignancy in follicular or
Hürthle cell neoplasms as shown by the chi-square test
were: sex, volume of the thyroid gland, and Tg concen-
tration (Table 1). The independent predictors of malig-
nancy as shown by multivariate logistic regression were:
sex and preoperative Tg concentration (Table 4). Male
patients had a higher risk of carcinoma than female pa-
tients (odds ratio, 2.57). In male patients, the malignancy
rate was 43%, while in female patients, it was 23%. Patients
with a preoperative Tg concentration of 80 ng/ml or
higher had a higher risk of malignancy than those with a
Table 2 Tumor size, presence of carcinoma, and Tg concentration
Tumor size (cm) Number of patients Benign tumor median (range) Tg
concentration ng/ml
Carcinoma median (range) Tg
concentration ng/ml
P value
0.01 to 0.5 9 12 (11 to 27) 60 (1 to 974) 0.225
0.51 to 1 46 18 (1 to 839) 32 (2 to 441)
1.01 to 1.5 83 41 (2 to 1,026) 119 (3 to 3,424)
1.51 to 2 106 62 (3 to 860) 90 (1 to 1,757)
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Tg concentration of 80 ng/ml or more, the malignancy
rate was 35%, while in those with a smaller Tg concentra-
tion, it was 19%.
Incidental carcinoma in a non-dominant tumor was
detected in 13 patients. It was detected in patients with
a benign disease and carcinoma of the dominant nodule
in 9 (5%) and 4 (6%) of cases, respectively. In patients
with carcinoma in the dominant nodule, final pathology
additionally revealed a benign goiter, benign adenoma,
and thyroiditis in 21, 10, and 27 cases, respectively.
Discussion
The following predictive factors of malignancy have been
reported in the literature [5,13,14,17-41]: the patient’s
age [18,19,24,25,30-33] and sex [5,26], the tumor size
[5,18,20-22,24-26,31-36,42], a solitary nodule [24,26,27],
tumor fixation [25], a lesion that feels hard on palpation
[27], Tg concentration [13,14,18], ultrasound characte-
ristics [17,27-29,41], cytologic characteristic [21], and
gene expression diagnostic markers [37-40]. UltrasoundFigure 1 Serum Tg concentration and age of patients with
follicular and Hürthle cell neoplasms. +, with carcinoma; O,
without carcinoma.characteristics predictive of malignancy are: the presence
of internal blood flow (as detected by Doppler ultraso-
nography), the presence of hypervascularity, a solid echo
structure, a hypoechoic lesion, or microcalcifications
[17,27-29,41]. New cytologic characteristics were also
reported as factors predictive of malignancy: trans-
gressing vessel [21] and nuclear grooves [21]. New gene
expression diagnostic markers of malignancy are: miR-
100, miR-125b, miR-138, miR-768-3p, miRNA-885-5p,
and a combination of genes PVALB and C1orf24 [37-40].
However, a vast majority of reports on predictive factors
in follicular or Hürthle cell neoplasms included only a
small number of patients; thus, the authors of these
studies could perform only a univariate statistical ana-
lysis. To our knowledge, so far only eight publications
[13,14,17,18,21,25,26,41] have reported the results of
multivariate logistic regression analysis of predictive fac-
tors in patients with follicular or Hürthle cell neoplasms.
Carcangiu et al. [30], Lopez-Penabad et al. [31], Taneri
et al. [32], and Zhang et al. [33] stated that patients with
carcinoma were older than those with a benign disease.Figure 2 Serum Tg concentration and tumor size in follicular
and Hürthle cell neoplasms. +, with carcinoma; O, without
carcinoma.








Carcinoma 62 1 to 3,424 86
Follicular 10 2 to 3,424 72
Hürthle cell 11 1 to 1,757 106
Papillary, classic
type
9 1 to 974 85
Papillary,
follicular type




Benign tumor 182 1 to 1,203 41
Adenoma 115 1 to 1,026 32
Benign goiter 67 1 to 839 54
Benign tumors versus papillary carcinomas and versus follicular or Hürthle cell
carcinomas (P < 0.001).
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was not statistically different from the median age of
those with a benign disease (52.5 years versus 52 years).
Our findings are in agreement with the majority of reports
from the literature.
Mihai et al. [5] and Tuttle et al. [26] found that the
risk of carcinoma was higher in men than in women.
This is in agreement with the findings of our study. In
our study, men had a higher risk of carcinoma than
women (an odds ratio of 2.57). The malignancy rate in
men in our study was 43%, while in women it was 23%.
Many authors reported that the size of follicular neo-
plasms increases the risk of malignancy [5,18,20-22,
24-26,28,31-36,42]. Tuttle et al. [26] reported that the
risk of carcinoma in a tumor larger than 4 cm was 40%,
while in smaller tumors it was only 13%. In our patients
with a tumor diameter of 2 cm or less, the risk of carcin-
oma was 25.5%. In Hürthle cell neoplasms, Taneri et al.
[32] found that there was no malignancy among the
tumors less than 1 cm in diameter. But our findings are
quite the opposite. In our patients, the malignancy rate
did not differ in patients with a tumor diameter of 1 cm
or less versus bigger tumors (Table 1).Table 4 Independent risk factors for malignancy in
follicular or Hürthle cell neoplasms
Factor Subgroup Odds ratio 95% confidence
interval




79 or less 1 1.30 to 4.25
80 or more 2.35
The likelihood of malignancy as calculated by logistic regression (model summary:
chi-square: 13.747; 2 degrees of freedom; P = 0.002; −2 log likelihood of 263.32).Hocevar and Auersperg [12] found that preoperative
Tg concentration was higher in patients with follicular
and Hürthle cell carcinoma than in patients with be-
nign tumors. In Hürthle cell neoplasms, Sugino et al.
[42] reported that in patients with carcinoma and benign
disease the median Tg concentration was 1,782 ng/ml and
573 ng/ml, respectively. Strazisar et al. [14] and Petric
et al. [13] reported that there was a statistical difference in
preoperative Tg concentrations of benign tumors, papil-
lary carcinomas, follicular carcinomas, and Hürthle cell
carcinomas. Moreover, the results of the present study
show that the mean preoperative Tg concentration was
significantly different (P < 0.05) in benign tumors, papil-
lary carcinomas, follicular carcinomas, and Hürthle cell
carcinomas. The median preoperative Tg concentrations
in benign tumors, papillary carcinomas, follicular carcin-
omas, and Hürthle cell carcinomas were 41, 87, 72, and
106 ng/ml, respectively. However, in contrast to our
findings, Suh et al. [23] found, in only 39 patients
with follicular or Hürthle cell neoplasms, that Tg was
not an independent risk factor [23]. The median preopera-
tive levels of the Tg serum were, in patients with malig-
nant and in patients with benign tumors, 135 ng/ml and
116 ng/ml, respectively [23]. Their patients had bigger
tumors than did the patients from our present study.
Their patients’ Tg concentrations were larger than ours,
probably because the median tumor size of their patients
was bigger than in our study. The median diameter of
their malignant and benign tumors was 2.8 cm and
2.4 cm, respectively.
The aim of this study was to find out whether Tg is a
predictive factor of malignancy in 244 small (2 cm or
less) follicular or Hürthle cell neoplasms. In our study,
the concentration of Tg was an independent predictive
factor of malignancy. Patients with a preoperative Tg
concentration of at least 80 ng/ml had a higher risk of
malignancy than those with a lower concentration (an
odds ratio of 2.35). In patients with a Tg concentration
of 80 ng/ml or more, the malignancy rate was 35%, while
in those with a smaller Tg concentration, it was only
19%. We believe that determination of Tg concentration
may be one of the factors that are useful in follicular or
Hürthle cell neoplasms before determining the extent of
the thyroid surgical procedure.
Conclusions
The malignancy rate in this study of 244 patients with fol-
licular or Hürthle cell neoplasms with a tumor diameter
of 2 cm or less was 25.5%. The independent predictors of
malignancy in follicular or Hürthle cell neoplasms are: sex
and preoperative Tg concentration.
Abbreviations
FNAB: fine-needle aspiration biopsy; ROC: receiver operating characteristic;
Tg: thyroglobulin.
Petric et al. World Journal of Surgical Oncology 2014, 12:282 Page 6 of 7
http://www.wjso.com/content/12/1/282Competing interests
The authors declare that there are no competing interests that could be
perceived as prejudicing the impartiality of this paper.
Authors’ contributions
RP participated in the design of the study, collected data, performed the
statistical analysis, and drafted the manuscript. NB participated in the design
of the study and drafted the manuscript. HB collected data. All authors read
and approved the final manuscript.
Acknowledgement
This paper is a part of Research Study No. P3-0289 supported by the Ministry
of Higher Education, Science, and Technology of the Republic of Slovenia.
Received: 10 July 2014 Accepted: 2 September 2014
Published: 12 September 2014
References
1. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid
Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM,
Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F,
Schlumberger M, Sherman SI, Steward DL, Tuttle RM: Revised American
Thyroid Association management guidelines for patients with thyroid
nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167–1214.
2. Hegedus L: Clinical practice. The thyroid nodule. N Engl J Med 2004,
351:1764–1771.
3. Baloch ZW, LiVolsi VA: Our approach to follicular-patterned lesions of the
thyroid. J Clin Pathol 2007, 60:244–250.
4. DeMay RM: Follicular lesions of the thyroid. Am J Clin Pathol 2000,
114:681–683.
5. Mihai R, Parker AJ, Roskell D, Sadler GP: One in four patients with follicular
thyroid cytology (THY3) has a thyroid carcinoma. Thyroid 2009, 19:33–37.
6. Hedinger C, Wiliams ED, Sobin LH: The WHO histological classification of
thyroid tumors: a commentary on the second edition. Cancer 1989,
63:908–911.
7. Rosai J: Tumors of the thyroid gland. In Atlas of Tumor Pathology. Edited by
Rosai J, Carcangiu ML, Delellis RA. Washington: Armed Forces Institute of
Pathology; 1992:31–50.
8. Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK: Diagnosis of ‘follicular
neoplasm’: a gray zone in thyroid fine-needle aspiration cytology.
Diagn Cytopathol 2002, 26:41–44.
9. Baloch ZW, LiVolsi VA: Fine-needle aspiration of the thyroid: today and
tomorrow. Best Pract Res Clin Endocrinol Metab 2008, 22:929–939.
10. Lumachi F, Borsato S, Tregnaghi A, Marino F, Polistina F, Basso SM, Koussis
H, Basso U, Fassina A: FNA cytology and frozen section examination in
patients with follicular lesions of the thyroid gland. Anticancer Res 2009,
29:5255–5257.
11. Udelsman R, Westra WH, Donovan PI, Sohn TA, Cameron JL: Randomized
prospective evaluation of frozen-section analysis for follicular lesions of
the thyroid. Ann Surg 2001, 233:716–722.
12. Hocevar M, Auersperg M: Role of serum thyroglobulin in the pre-
operative evaluation of follicular thyroid tumors. Eur J Surg Oncol 1998,
24:553–557.
13. Petric R, Perhavec A, Gazic B, Besic N: Preoperative serum thyroglobulin
concentration is an independent predictive factor of malignancy in
follicular neoplasms of the thyroid gland. J Surg Oncol 2012, 105:351–356.
14. Strazisar B, Petric R, Sesek M, Zgajnar J, Hocevar M, Besic N: Predictive
factors of carcinoma in 279 patients with Hürthle cell neoplasm of the
thyroid gland. J Surg Oncol 2010, 101:582–586.
15. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W,
European Thyroid Cancer Taskforce: European consensus for the
management of patients with differentiated thyroid carcinoma of the
follicular epithelium. Eur J Endocrinol 2006, 154:787–803.
16. Rasmussen LB, Ovesen L, Bülow I, Jørgensen T, Knudsen N, Laurberg P,
Perrild H: Relations between various measures of iodine intake and
thyroid volume, thyroid nodularity, and serum thyroglobulin. Am J Clin
Nutr 2002, 76:1069–1076.
17. Ho AS, Sarti EE, Jain KS, Wang H, Nixon IJ, Shaha AR, Shah JP, Kraus DH,
Ghossein R, Fish SA, Wong RJ, Lin O, Morris LG: Malignancy rate in thyroid
nodules classified as Bethesda Category III (AUS/FLUS). Thyroid 2013,
24:832–839.18. Besic N, Sesek M, Peric B, Zgajnar J, Hocevar M: Predictive factors of
carcinoma in 327 patients with follicular neoplasm of the thyroid.
Med Sci Monit 2008, 14:CR459–CR467.
19. Tyler DS, Winchester DJ, Caraway NP, Hickey RC, Evans DB: Indeterminate
fine-needle aspiration biopsy of the thyroid: identification of
subgroups at high risk for invasive carcinoma. Surgery 1994,
116:1054–1060.
20. Heikkilä A, Siironen P, Hagström J, Heiskanen I, Sankila R, Louhimo J,
Haglund C, Arola J: Follicular thyroid neoplasm: clinicopathologic features
suggesting malignancy. APMIS 2010, 118:846–854.
21. Lubitz CC, Faquin WC, Yang J, Mekel M, Gaz RD, Parangi S,
Randolph GW, Hodin RA, Stephen AE: Clinical and cytological features
predictive of malignancy in thyroid follicular neoplasms. Thyroid 2010,
20:25–31.
22. Raparia K, Min SK, Mody DR, Anton R, Amrikachi M: Clinical outcomes for
‘suspicious’ category in thyroid fine-needle aspiration biopsy: patient’s
sex and nodule size are possible predictors of malignancy. Arch Pathol
Lab Med 2009, 133:787–790.
23. Suh I, Vriens MR, Guerrero MA, Griffin A, Shen WT, Duh QY, Clark OH,
Kebebew E: Serum thyroglobulin is a poor diagnostic biomarker of
malignancy in follicular and Hürthle-cell neoplasms of the thyroid.
Am J Surg 2010, 200:41–46.
24. Paramo JC, Mesko T: Age, tumor size, and in-office ultrasonography are
predictive parameters of malignancy in follicular neoplasms of the
thyroid. Endocr Pract 2008, 14:447–451.
25. Schlinkert RT, van Heerden JA, Goellner JR, Gharib H, Smith SL,
Rosales RF, Weaver AL: Factors that predict malignant thyroid lesions
when fine-needle aspiration is ‘suspicious for follicular neoplasm’.
Mayo Clin Proc 1997, 72:913–916.
26. Tuttle RM, Lemar H, Burch HB: Clinical features associated with an
increased risk of thyroid malignancy in patients with follicular neoplasia
by fine-needle aspiration. Thyroid 1998, 8:377–383.
27. Raber W, Kaserer K, Niederle B, Vierhapper H: Risk factors for malignancy of
thyroid nodules initially identified as follicular neoplasia by fine-needle
aspiration: results of a prospective study of one hundred twenty
patients. Thyroid 2000, 10:709–712.
28. Gulcelik NE, Gulcelik MA, Kuru B: Risk of malignancy in patients with
follicular neoplasm: predictive value of clinical and ultrasonographic
features. Arch Otolaryngol Head Neck Surg 2008, 134:1312–1315.
29. Choi YJ, Yun JS, Kim DH: Clinical and ultrasound features of cytology
diagnosed follicular neoplasm. Endocr J 2009, 56:383–389.
30. Carcangiu ML, Bianchi S, Savino D, Voynick IM, Rosai J: Follicular Hürthle
cell tumors of the thyroid gland. Cancer 1991, 68:1944–1953.
31. Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordoñez NG,
Sherman SI: Prognostic factors in patients with Hürthle cell neoplasms of
the thyroid. Cancer 2003, 97:1186–1194.
32. Taneri F, Tekin E, Salman B, Anadol AZ, Ersoy E, Poyraz A, Onuk E: Hürthle
cell neoplasms of the thyroid: predicting malignant potential. Endocr
Regul 2000, 34:19–21.
33. Zhang YW, Greenblatta DY, Repplingera D, Bargren A, Adler JT, Sippel RS,
Chen H: Factors that predict malignancy in Hürthle cell neoplasms of the
thyroid. J Surg Res 2008, 144:371–2.
34. Chen H, Nicol TL, Zeiger MA, Dooley WC, Ladenson PW, Cooper DS,
Ringel M, Parkerson S, Allo M, Udelsman R: Hürthle cell neoplasms of the
thyroid: are these factors predictive of malignancy? Ann Surgery 1998,
227:542–546.
35. Pisanu A, Sias L, Uccheddu A: Factors predicting malignancy of Hürthle
cell tumors of the thyroid: influence on surgical treatment. World J Surg
2004, 28:761–765.
36. Sippel RS, Elaraj DM, Khanafshar E, Zarnegar R, Kebebew E, Duh QY,
Clark OH: Tumor size predicts malignant potential in Hürthle cell
neoplasms of the thyroid. World J Surg 2008, 32:702–707.
37. Freitas BC, Cerutti J: Genetic markers differentiating follicular thyroid
carcinoma from benign lesions. Moll Cell Endocrinol 2010, 321:77–85.
38. Cerutti JM, Oler G, Delcelo R, Gerardt R, Michaluart P Jr, de Souza SJ,
Galante PA, Huang P, Riggins GJ: PVALB, a new Hürthle adenoma
diagnostic marker identified through gene expression. J Clin Endocrinol
Metab 2011, 96:E151–E160.
39. Vriens MR, Weng J, Suh I, Huynh N, Guerrero MA, Shen WT, Duh QY,
Clark OH, Kebebew E: MicroRNA expression profiling is a potential
diagnostic tool for thyroid cancer. Cancer 2012, 118:3426–3432.
Petric et al. World Journal of Surgical Oncology 2014, 12:282 Page 7 of 7
http://www.wjso.com/content/12/1/28240. Dettmer M, Vogetseder A, Durso MB, Moch H, Komminoth P, Perren A,
Nikiforov YE, Nikiforova MN: MicroRNA expression array identifies novel
diagnostic markers for conventional and oncocytic follicular thyroid
carcinomas. J Clin Endocrinol Metab 2013, 98:E1–E7.
41. Cuhaci N, Arpaci D, Ucler R, Yazgan AK, Kıyak G, Yalçin S, Ersoy PE, Güler G,
Ersoy R, Cakir B: Malignancy rate of thyroid nodules defined as follicular
lesion of undetermined significance and atypia of undetermined
significance in thyroid cytopathology and its relation with ultrasonographic
features. Endocr Pathol 2014. doi:10.1007/s12022-014-9298-7.
42. Sugino K, Ito K, Mimura T, Kameyama K, Iwasaki H, Ito K: Hürthle cell tumor
of the thyroid: analysis of 188 cases. World J Surg 2001, 25:1160–1163.
doi:10.1186/1477-7819-12-282
Cite this article as: Petric et al.: Preoperative serum thyroglobulin
concentration as a predictive factor of malignancy in small follicular and
Hürthle cell neoplasms of the thyroid gland. World Journal of Surgical
Oncology 2014 12:282.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
